Myostatin as a fibroblast‐activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma
Myostatin as a fibroblast‐activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma
复制标题
DOI：
10.1111/hepr.13667
复制
发表时间：
2021-05
影响因子：
4.2
通讯作者：
Sachiyo Yoshio;Tomonari Shimagaki;R. Hashida;T. Kawaguchi;Y. Tsutsui;Y. Sakamoto;Y. Yoshida;Hironari Kawai;Shiori Yoshikawa;Taiji Yamazoe;Taizo Mori;Y. Osawa;S. Itoh;M. Fukai;T. Yoshizumi;A. Taketomi;M. Mori;T. Kanto
中科院分区：
文献类型：
--
作者：
Sachiyo Yoshio;Tomonari Shimagaki;R. Hashida;T. Kawaguchi;Y. Tsutsui;Y. Sakamoto;Y. Yoshida;Hironari Kawai;Shiori Yoshikawa;Taiji Yamazoe;Taizo Mori;Y. Osawa;S. Itoh;M. Fukai;T. Yoshizumi;A. Taketomi;M. Mori;T. Kanto
在肝硬化患者中，血清肌生长抑制素水平高与预后不良相关。我们的目的是阐明肌肉生长抑制素对无肝硬化的非酒精性脂肪性肝病-肝细胞癌（NAFLD‐HCC）患者预后和肝纤维化进展的影响。
In patients with liver cirrhosis, high levels of serum myostatin are associated with poor prognosis. We aimed to clarify the influence of myostatin on the prognosis of patients with non‐alcoholic fatty liver disease–hepatocellular carcinoma (NAFLD‐HCC) without cirrhosis and on the progression of liver fibrosis.